Lisinopril Bone Health and Density Impact: What the Evidence Shows
Lisinopril is an ACE (angiotensin-converting enzyme) inhibitor sold under brand names including Zestril and Prinivil, prescribed for hypertension, heart failure with reduced ejection fraction, post-myocardial-infarction left ventricular dysfunction, and diabetic kidney disease. It is not FDA-approved or studied as a bone or osteoporosis therapy. This article addresses a narrower and more useful question than "does lisinopril affect bones": whether its observed association with bone mineral density should change how clinicians choose or monitor antihypertensive therapy in patients who also have, or are at risk for, osteoporosis.
Lisinopril has not been shown in any randomized trial to increase or decrease fracture risk, because no trial of lisinopril has used fracture or bone mineral density as a primary outcome. Observational cohort studies report modestly higher bone mineral density and somewhat lower fracture odds among ACE inhibitor users compared with non-users, but confounding by body weight, physical activity, and the health conditions that lead to an ACE inhibitor prescription in the first place limits how much can be concluded from that association. No guideline recommends lisinopril, or any ACE inhibitor, as a bone-protective therapy, and clinicians should not delay standard osteoporosis screening or bisphosphonate therapy on the assumption that lisinopril is doing protective work.
The mechanism: plausible, not proven in humans
Angiotensin II is not only a vasoconstrictor. Preclinical work has identified AT1 receptors on osteoblasts and osteoclasts, and animal studies suggest angiotensin II signaling can upregulate RANKL, the cytokine that drives osteoclast formation and bone resorption, while impairing osteoblast differentiation through Wnt-pathway inhibition. By reducing angiotensin II production, lisinopril could in principle tilt this balance toward less resorption and more formation.
This mechanism is biologically coherent and has support from rodent and cell-culture studies, but it has not been confirmed as a clinically meaningful effect in humans on lisinopril specifically. ACE inhibitors also reduce bradykinin breakdown, and bradykinin has been proposed to stimulate osteoblast activity through prostaglandin pathways in vitro. Whether this translates into measurable density gains in patients taking lisinopril for years is unconfirmed. Readers should treat this section as an explanation of biological plausibility, not as evidence of a clinical benefit.
What the observational human data actually show
Several cohort and case-control studies have examined bone mineral density and fracture rates in people taking ACE inhibitors, including analyses drawn from large osteoporosis cohorts and prescription databases. The general pattern across this literature is:
- ACE inhibitor users tend to show slightly higher hip or femoral neck bone mineral density than non-users, typically in the range of low single-digit percentage differences, which falls short of the magnitude usually considered clinically meaningful on its own.
- Some case-control and cohort analyses report modestly lower fracture odds in ACE inhibitor users, with point estimates in past literature clustering in the range of roughly 10 to 15 percent lower odds, though confidence intervals and study quality vary.
- A meta-analysis of antihypertensive drug classes and fracture risk found a similar direction of effect for ACE inhibitors as a class, but flagged substantial heterogeneity between studies and cautioned against causal interpretation.
The exact effect sizes cited in earlier versions of this article, and in much of the surrounding literature, require verification against the original primary papers before being presented as fixed numbers; this draft intentionally avoids restating precise point estimates and confidence intervals that cannot be independently confirmed here. The consistent, defensible summary is: the direction of the observational signal favors a small, non-harmful, possibly mildly protective association, not a harmful one, and it is too small and too confounded to guide drug selection on its own.
A recurring confounder in this literature is confounding by indication and by body weight. Patients prescribed ACE inhibitors often differ systematically from those who are not, in ways (body mass, activity level, comorbidity burden) that independently affect bone density and fracture risk. None of the available observational studies fully resolves this.
Sex-specific data are sparser still. Some cross-sectional work suggests postmenopausal women, in whom estrogen loss accelerates angiotensin-II-driven resorption, may show a more detectable ACE inhibitor association than men, but this has not been replicated in a way that supports a specific numeric estimate here.
Why ALLHAT cannot answer the bone question
ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) randomized more than 30,000 high-risk hypertensive patients to chlorthalidone, amlodipine, or lisinopril, with a primary outcome of fatal coronary disease or nonfatal MI. Published in JAMA in 2002, the trial found lisinopril statistically equivalent to chlorthalidone on the primary outcome but with a higher rate of stroke and combined cardiovascular disease.
ALLHAT did not collect bone mineral density data and did not report fracture incidence as an outcome. It is sometimes cited as if it settles a lisinopril-versus-thiazide bone comparison; it does not, because the trial was never designed to measure that. Thiazide-type diuretics reduce urinary calcium excretion and have independent evidence for a modest bone benefit, so any comparison between lisinopril and chlorthalidone on skeletal grounds has to come from separate thiazide-specific fracture studies, not from ALLHAT.
The complication that matters more than the mechanism: chronic kidney disease
Lisinopril is frequently used in patients with diabetic nephropathy or proteinuric chronic kidney disease, and this is where the bone picture becomes genuinely complicated rather than reassuring.
As kidney function declines, phosphate retention stimulates FGF-23, which suppresses the renal enzyme that activates vitamin D. Falling calcitriol contributes to secondary hyperparathyroidism, and elevated parathyroid hormone can drive high-turnover bone disease, while low calcitriol can separately contribute to low-turnover (adynamic) bone disease. The combined effect on bone quality is unpredictable and is not something standard DXA scanning fully captures, because CKD-related bone disease can alter bone strength without an equivalent change in density.
Lisinopril's renoprotective effect, by slowing the decline in kidney function, may plausibly delay the onset of these mineral-metabolism disturbances. That is a reasonable extension of its known renal pharmacology, but it has not been tested as a bone-outcome hypothesis in a prospective trial. It should be described as plausible, not established.
For patients with CKD stage 3b or beyond on lisinopril, mineral-metabolism monitoring should follow KDIGO CKD-MBD guidance rather than any lisinopril-specific schedule: periodic serum calcium, phosphate, parathyroid hormone, and 25-OH vitamin D, with frequency increasing as kidney function declines. Bone mineral density testing in this population should be interpreted cautiously, since it can underestimate fracture risk when bone quality is deteriorating independently of density.
Vitamin D metabolism: a real but modest interaction
The renin-angiotensin system and vitamin D metabolism are linked. Angiotensin II suppresses the renal enzyme (1-alpha-hydroxylase) that converts 25-OH vitamin D into its active hormonal form, 1,25-dihydroxyvitamin D. By lowering angiotensin II, lisinopril may partially relieve that suppression and nudge active vitamin D production upward. Some population-level analyses have reported higher active vitamin D levels in ACE inhibitor users compared with matched non-users, without a corresponding difference in storage-form (25-OH) vitamin D.
This is a real, mechanistically grounded pathway, but the magnitude reported in the literature is modest, and the specific numbers attached to it in earlier drafts of this topic should be treated as unverified until checked against the original source. Practically, this pathway does not change any current recommendation about vitamin D supplementation for patients on lisinopril; supplementation decisions should still follow standard osteoporosis and CKD-MBD guidance rather than ACE inhibitor status.
Drug interactions and combination therapy relevant to bone health
NSAIDs. NSAIDs blunt the renal protective effect of ACE inhibition and can independently impair fracture healing. Concurrent use of lisinopril and chronic NSAIDs compounds both a renal and a skeletal concern and warrants closer monitoring of renal function.
Corticosteroids. Glucocorticoid-induced osteoporosis is the most common secondary cause of osteoporosis, and current rheumatology guidance recommends risk-stratifying patients on chronic corticosteroids above threshold doses and duration, independent of what antihypertensive they take. Any modest bone-preserving signal attributed to lisinopril is not large enough to offset the catabolic effect of chronic corticosteroid use, and corticosteroid-related fracture risk should be assessed on its own terms.
Bisphosphonates. There is no known pharmacokinetic or pharmacodynamic interaction between lisinopril and oral bisphosphonates such as alendronate or risedronate; both can be prescribed together. The practical monitoring issue arises if a potassium-sparing diuretic is added to this combination for edema, since lisinopril already raises serum potassium: renal function and potassium should be rechecked several weeks after any such regimen change.
Falls, not just density, drive real-world fracture risk in older adults
For many older patients, the pathway from antihypertensive medication to fracture runs through falls, not through bone density. Any blood-pressure-lowering drug can produce orthostatic hypotension, particularly at initiation or in volume-depleted patients, and falls are a more immediate fracture risk in frail older adults than a one or two percent BMD difference. Lisinopril is not flagged as a high fall-risk medication in geriatric prescribing criteria the way some other drug classes are, but checking orthostatic vitals at initiation, especially in patients over 70 or those on concurrent alpha-blocker therapy for benign prostatic hyperplasia, is a reasonable practical safeguard that has nothing to do with lisinopril's effect on bone tissue itself.
What this means for choosing an antihypertensive when bone health is a concern
The evidence above does not support choosing or avoiding lisinopril on bone grounds. It does support a structured way of thinking through the decision when a patient has both a blood pressure indication and an osteoporosis-relevant risk factor.
| Clinical situation | What the evidence supports | What it does not support |
|---|---|---|
| Patient needs an antihypertensive, no CKD, no osteoporosis diagnosis | Standard USPSTF-based screening applies regardless of drug choice; lisinopril is a reasonable option on its own cardiovascular and renal merits | Choosing lisinopril specifically for bone protection |
| Patient has osteoporosis or osteopenia and multiple antihypertensive options are medically appropriate | A thiazide-type diuretic (e.g., chlorthalidone, hydrochlorothiazide) has more consistent fracture-related observational and trial-adjacent evidence and can reasonably be favored if cardiovascular indication permits | Assuming lisinopril is equivalent to a thiazide on bone outcomes; no head-to-head fracture trial supports that |
| Patient has proteinuric CKD or diabetic nephropathy | Lisinopril's renoprotective effect is well established and is the dominant clinical consideration; any indirect bone benefit from slowing CKD progression is plausible but unproven | Treating renoprotection as equivalent to a proven bone benefit, or skipping CKD-MBD labs because the patient is "protected" by lisinopril |
| Patient is on chronic corticosteroids | Follow glucocorticoid-induced osteoporosis risk stratification independent of antihypertensive choice | Assuming lisinopril offsets corticosteroid-related bone loss |
| Patient meets T-score or FRAX threshold for pharmacologic osteoporosis therapy | Start guideline-directed therapy (e.g., a bisphosphonate) regardless of lisinopril use; there is no interaction that should delay this | Waiting to see if lisinopril "helps" bone density before starting therapy |
| Patient is over 70, starting lisinopril, or on concurrent alpha-blocker therapy | Check orthostatic vitals at initiation to reduce fall-related fracture risk | Assuming bone density data are more relevant than fall risk in this population |
The rule of thumb this table encodes: decide on lisinopril using its established cardiovascular and renal indications, decide on bone-specific therapy using standard osteoporosis criteria, and treat any bone mineral density association as background information that should not delay or substitute for either decision.
Monitoring: what is actually recommended
Patients on lisinopril do not need bone-specific monitoring beyond standard age- and risk-based osteoporosis screening. The USPSTF recommends dual-energy X-ray absorptiometry (DXA) screening for women aged 65 and older, and for younger postmenopausal women whose fracture risk, estimated using a validated tool, is equivalent to that of a 65-year-old woman without additional risk factors (USPSTF, 2018 recommendation). Men are not covered by a USPSTF recommendation for routine screening; some specialty guidelines suggest considering screening in older men with clinical risk factors, and that decision should be individualized with a clinician rather than driven by antihypertensive drug choice.
For patients with CKD stage 3b or beyond on lisinopril, mineral-metabolism labs (calcium, phosphate, parathyroid hormone, 25-OH vitamin D) should follow CKD-MBD guideline intervals, which generally call for more frequent monitoring as kidney function declines. This schedule is driven by kidney function stage, not by lisinopril use itself.
No current guideline recommends starting or continuing lisinopril specifically for bone protection, and no guideline recommends delaying bisphosphonate therapy in a patient who meets standard treatment thresholds because they are also on lisinopril.
What is established, what is plausible, and what is not established
Established: Lisinopril has no known direct bone-toxic effect. Bisphosphonates and lisinopril can be co-prescribed without a pharmacokinetic interaction. Standard USPSTF osteoporosis screening criteria apply to patients on lisinopril without modification.
Plausible but unproven: A small, favorable effect of ACE inhibition on bone mineral density and fracture odds, mediated through reduced angiotensin II signaling and possibly through modest increases in active vitamin D. An indirect bone benefit from lisinopril's renoprotective effect in CKD, by delaying secondary hyperparathyroidism and FGF-23-driven bone disease.
Not established: That lisinopril meaningfully reduces fracture risk in a way that should influence antihypertensive selection for most patients. That lisinopril is equivalent or superior to thiazide diuretics on bone outcomes. Any precise numeric effect size for BMD change, fracture odds ratio, or vitamin D level difference attributable to lisinopril; the observational literature in this area is heterogeneous, and specific figures should be checked against the original studies before being used in a clinical or patient-facing context.
When to seek urgent evaluation
A new fracture after a low-energy fall, sudden new back pain with height loss, or symptoms of severe hypocalcemia (muscle cramps, perioral numbness, tetany) in a patient with CKD warrant prompt medical evaluation rather than watchful waiting, regardless of antihypertensive regimen. Lightheadedness or fainting shortly after starting or increasing lisinopril also warrants medical contact, since it may signal excessive blood pressure lowering and fall risk rather than a bone-specific problem.
Frequently asked questions
Frequently asked questions
Does lisinopril weaken bones?
Can lisinopril increase fracture risk?
Should I take a calcium supplement because I am on lisinopril?
Does lisinopril affect vitamin D levels?
Is lisinopril safe to use with bisphosphonates like alendronate?
Which blood pressure medication is best for someone with osteoporosis?
Does the ALLHAT trial tell us anything about bone health with lisinopril?
How does chronic kidney disease change the bone picture for someone on lisinopril?
What bone monitoring does someone on long-term lisinopril actually need?
References
- US Preventive Services Task Force. Osteoporosis to Prevent Fractures: Screening. 2018. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/osteoporosis-screening
The mechanistic and observational literature discussed above (angiotensin II and osteoclast/osteoblast biology, ACE inhibitor cohort studies, ALLHAT, KDIGO CKD-MBD guidance, glucocorticoid-induced osteoporosis guidance, and antihypertensive fracture meta-analyses) is drawn from published research areas that require verification against the original primary papers before specific effect sizes, confidence intervals, or direct quotations are used in a published or patient-facing version of this article. This draft has deliberately avoided restating unverified numeric point estimates and a previously included direct quotation that could not be confirmed against a checkable source.